Catalyst
Slingshot members are tracking this event:
FDAA approves Merck & co. (MRK) product KEYTRUDA® (pembrolizumab) for the treatment of non-squamous non-small cell lung cance (NSCLC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 10, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Non-squamous Non-small Cell Lung Cance, Nsclc, Keytruda, Pembrolizumab
